tiprankstipranks
Staar Surgical Company (CH:SR3)
NASDAQ:SR3

Staar Surgical (SR3) Price & Analysis

0 Followers

SR3 Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.

Bulls Say, Bears Say

Bulls Say
High Gross MarginsSustained gross margins near 75–76% indicate strong product economics for ICL lenses. With TTM revenue growth outpacing peers, high per-unit margins create durable operating leverage as volumes recover, supporting long-term profit potential once fixed costs are absorbed.
Healthy Balance SheetLow leverage and a sizable cash/investment balance provide financial flexibility to invest in manufacturing scale, product launches, and channel development without near-term refinancing risk. This buffer lowers execution risk during recovery phases and supports strategic initiatives.
Operational Turnaround In Q1The Q1 swing to strong revenue growth, positive adjusted EBITDA and materially higher margins shows that prior cost actions, product demand and channel normalization can quickly restore profitability, implying a clearer path to sustainable earnings if execution continues.
Bears Say
Negative Cash FlowMaterial negative operating and free cash flow in the TTM raises sustainability concerns: continued cash burn can force reduced investment, financing needs or dilution if losses reappear. Ability to convert recent EBITDA improvement into durable cash generation is unproven.
China Revenue ConcentrationRelying on one region for roughly half of sales magnifies exposure to local regulatory shifts, distributor dynamics, or demand cycles. Regional disruptions or policy changes in China could materially swing results and complicate predictability of global growth.
Pricing Pressure / ASP DeclinePersistent ASP declines mean higher volumes are required just to sustain revenue and margins. Even with premium SKUs like EVO+, sustained pricing pressure can erode unit economics and compress the high gross margins unless offset by mix, cost cuts, or new premium adoption.

Staar Surgical News

SR3 FAQ

What was Staar Surgical Company’s price range in the past 12 months?
Currently, no data Available
What is Staar Surgical Company’s market cap?
Staar Surgical Company’s market cap is CHF1.18B.
    When is Staar Surgical Company’s upcoming earnings report date?
    Staar Surgical Company’s upcoming earnings report date is Aug 12, 2026 which is in 45 days.
      How were Staar Surgical Company’s earnings last quarter?
      Staar Surgical Company released its earnings results on May 13, 2026. The company reported $0.324 earnings per share for the quarter, beating the consensus estimate of $0.043 by $0.281.
        Is Staar Surgical Company overvalued?
        According to Wall Street analysts Staar Surgical Company’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Staar Surgical Company pay dividends?
          Staar Surgical Company does not currently pay dividends.
          What is Staar Surgical Company’s EPS estimate?
          Staar Surgical Company’s EPS estimate is 0.18.
            How many shares outstanding does Staar Surgical Company have?
            Currently, no data Available
            What happened to Staar Surgical Company’s price movement after its last earnings report?
            Staar Surgical Company reported an EPS of $0.324 in its last earnings report, beating expectations of $0.043. Following the earnings report the stock price went same N/A.
              Which hedge fund is a major shareholder of Staar Surgical Company?
              Currently, no hedge funds are holding shares in CH:SR3
              What is the TipRanks Smart Score and how is it calculated?
              Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                Staar Surgical Stock Smart Score

                Company Description

                Staar Surgical Company

                STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.

                Staar Surgical (SR3) Earnings & Revenues

                SR3 Earnings Call

                Q1 2026
                0:00 / 0:00
                Earnings Call Sentiment|Positive
                The call conveyed a strong operational and financial turnaround in Q1 2026 highlighted by very strong revenue growth (+119.6% YoY), a return to profitability (adjusted EBITDA $24.4M), improved gross margins (73.6% vs. 65.8%), normalized distributor inventories in China, product launches (EVO+), and scalable Swiss manufacturing to avoid tariffs. Management emphasized cost discipline and a clearer path to sustainable profitability. Offsetting factors include geopolitical and regional headwinds (Middle East, India), near-term pricing pressure (ASP down high single digits), some lingering inventory and higher-cost product roll-through impacts, and conservative disclosure (no formal guidance) due to macro uncertainty and limited near-term visibility. Overall, the positive operational and financial momentum materially outweighs the listed challenges, though dependence on China and macro risks warrant continued monitoring.View all CH:SR3 earnings summaries

                SR3 Stock 12 Month Forecast

                Average Price Target

                $26.43
                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
                Similar Stocks
                Company
                Price & Change
                Follow
                Cooper Co
                Stevanato Group
                Bausch + Lomb Corporation
                Popular Stocks